Last update 21 Nov 2024
Amlodipine Besylate/Azilsartan/Hydrochlorothiazide
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Amlodipine/azilsartan/hydrochlorothiazide, Amlodipine/hydrochlorothiazide/azilsartan, Azilsartan/amlodipine/hydrochlorothiazide + [5] |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), CYP1A2 inhibitors(Cytochrome P450 1A2 inhibitors), NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors) + [1] |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC26H31ClN2O8S |
InChIKeyZPBWCRDSRKPIDG-UHFFFAOYSA-N |
CAS Registry111470-99-6 |
View All Structures (3)
Related
3
Clinical Trials associated with Amlodipine Besylate/Azilsartan/HydrochlorothiazideA Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Food-Effect of Single Oral Dose Administration of TAK-536TCH Final Formulation Tablet in Healthy Adult Male Subjects
A Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Food-Effect of Single Oral Dose of TAK-536TCH Final Formulation Tablet in Healthy Adult Male Subjects
A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety and Efficacy of TAK-536, Amlodipine and Hydrochlorothiazide in Subjects With Essential Hypertension
100 Clinical Results associated with Amlodipine Besylate/Azilsartan/Hydrochlorothiazide
Login to view more data
100 Translational Medicine associated with Amlodipine Besylate/Azilsartan/Hydrochlorothiazide
Login to view more data
100 Patents (Medical) associated with Amlodipine Besylate/Azilsartan/Hydrochlorothiazide
Login to view more data
100 Deals associated with Amlodipine Besylate/Azilsartan/Hydrochlorothiazide
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Essential Hypertension | NDA/BLA | JP | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 341 | (coupooosym) = soqhduvcpm mtlbfkjjgk (mjitdacpaz, zlemjhegfi - xuinrbclgw) View more | - | 26 Jun 2017 | |||
Phase 1 | 12 | (TAK-536TCH Fasted) | fbrvirmkhu(omtkfqbvii) = pdhzrthqjg flykcmuupp (rpflzcngmn, mewxkieznl - ijcvwjjlhq) View more | - | 26 Apr 2016 | ||
(TAK-536TCH Fed) | fbrvirmkhu(omtkfqbvii) = pxghnrdldm flykcmuupp (rpflzcngmn, inctvjrhps - ixjnrxusjl) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free